Lupus nephritis as a specific clinical and immunological phenotype of systemic lupus erythematosus

Lupus nephritis (LN) is the leading cause of death in systemic lupus erythematosus (SLE), so its early detection and treatment is of utmost importance. Features of the onset, clinical signs, certain morphological classes, as well as more aggressive therapy make it possible to assign SLE with LN to a distinct disease phenotype.

Objective: to characterize the clinical, immunological and morphological features of the SLE phenotype with a predominant kidney involvement based on a comparative analysis of patients with LN and without LN.

Patients and methods. The study included 400 patients with SLE who met the 2012 SLICC criteria and were hospitalized to V.A. Nasonova Research Institute of Rheumatology from 2013 to 2021. The diagnosis of LN was established in 192 (48%) patients, of which in 82 (43%) it was confirmed by pathological study of kidney biopsy specimens (the SLE group with LN). In 208 (52%) patients, no kidney damage was observed, and they constituted the SLE group without LN.

All patients underwent a standard examination with an assessment of disease activity according to the SLEDAI-2K index, irreversible changes in organs according to the SLICC damage index, immunological disorders, clinical and biochemical blood tests, urinalysis according to unified methods, glomerular filtration rate, as well as pathological examination of kidney biopsy specimens for confirmation of LN in the presence of an appropriate clinical picture. In patients of both groups, a comparative study of the main clinical, laboratory, immunological manifestations of SLE, the features of the disease onset, its first clinical signs, possible trigger factors, and the drugs used was carried out.

Results and discussion. In the LN group, insolation was more likely to trigger the development of SLE than in the group without LN (respectively, in 26% and 13% of cases; p=0.007). In turn, SLE without kidney damage more often than SLE with LN debuted during pregnancy or after childbirth.

The first signs of the disease in almost 40% of patients with LN were proteinuria and/or changes in urinary sediment, edema, increased blood pressure, the development of LN in some cases was preceded by polyarthritis or combined lesions of the skin and joints, but no later than 6 months, signs of kidney damage appeared. In the SLE group without LN, polyarthritis (in 33%), combined lesions of the skin and joints (in 26%), and Raynaud's syndrome (in 16%; p <0.0001) were more often observed at the onset. In patients with LN, erythematous lesions of the facial skin ("butterfly", in 42%), serositis (exudative pleuritis — in 44%, pericarditis — in 46%, ascites and hydrothorax — in 5%; p<0.0001), as well as hematological disorders such as anemia (in 63%), leukopenia (in 49%) and thrombocytopenia (in 42%) were present more frequently. With the development of LN, an acute course and high activity of the disease occurred significantly more often. In the study of immunological parameters in the group without LN, lupus anticoagulant (in 6%) and antibodies to SS-A/Ro and SS-B/La (in 18 and 9% of patients, respectively) were detected significantly more often, while in the LN group — hypocomplementemia (in 81%; p<0.0001). Therapy also differed significantly: patients with LN received higher doses of glucocorticoids (p<0.0001), mycophenolate mofetil, and cyclophosphamide.

Conclusion. SLE with LN can be considered a distinct disease phenotype with a set of characteristics (clinical and laboratory parameters, response to therapy, prognosis) that distinguish it from other SLE variants.

1. Bastian H, Roseman J, Mcgwin G, et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis, Lupus. 2002;11(3):152-60. doi: 10.1191/0961203302lu158oa.

2. Jakes, R, Bae S, Louthrenoo W, et al. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken). 2012 Feb;64(2):159-68. doi: 10.1002/acr.20683.

3. Bernatsky S, Boivin J, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012 Feb;64(2): 159-68. doi: 10.1002/acr.20683.

4. Faurschou M, Starklint H, Halberg P, Jacobsen S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol. 2006 Aug;33(8):1563-9.

5. Thompson JC, Mahajan A, Scott DA, Gairy K. The Economic Burden of Lupus Nephritis: A Systematic Literature Review. Rheumatol Ther. 2022 Feb;9(1):25-47. doi: 10.1007/s40744-021-00368-y.

6. Wakasugi D, Gono T, Kawaguchi Y, et al. Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: an analysis of predictive measures. J Rheumatol. 2012 Jan;39(1):79-85. doi: 10.3899/jrheum.110532.

7. Christopher-Stine L, Siedner M, Lin J, et al. Renal biopsy in lupus patients with low levels of proteinuria. J Rheumatol. 2007 Feb; 34(2):332-5.

8. Olson SW, Lee JJ, Prince LK, et al. Elevated subclinical double-stranded DNA antibodies and future proliferative lupus nephritis. Clin J Am Soc Nephrol. 2013 Oct;8(10): 1702-8. doi: 10.2215/CJN.01910213. Epub 2013 Jul 5.

9. Stojan G, Petri M. Anti-C1q in systemic lupus erythematosus. Lupus. 2016 Jul;25(8): 873-7. doi: 10.1177/0961203316645205.

10. Bruce I, Isenberg D, Wallace D, et al. Anti-C1q antibodies in systemic lupus erythematosus. Lupus. 2015 Jan;24(1):42-9. doi: 10.1177/0961203314547791. Epub 2014 Aug 14.

11. Rovin B. Glomerular disease: Lupus nephritis treatment: are we beyond cyclophoshamide? Nat Rev Nephrol. 2009 Sep;5(9): 492-4. doi: 10.1038/nrneph.2009.130.

12. Hu W, Chen Y, Wang S, et al. Clinical-Morphological Features and Outcomes of Lupus Podocytopathy. Clin J Am Soc Nephrol. 2016 Apr 7;11(4):585-92. doi: 10.2215/CJN.06720615. Epub 2016 Mar 16.

13. Song D, Wu L, Wang F, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. 2013 Jan 15;15(1):R12. doi: 10.1186/ar4142.

14. Weening J, D'Agati V, Schwartz M, et al; International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004 Feb;65(2):521-30. doi: 10.1111/j.1523-1755.2004.00443.x.

15. Fanouriakis A, Kostopoulou M, Chee-ma K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020 Jun; 79(6):713-23. doi: 10.1136/annrheumdis-2020-216924. Epub 2020 Mar 27.

16. Furie R, Rovin B, Houssiau F, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020 Sep 17;383(12):1117-28. doi: 10.1056/NEJMoa2001180

17. Petri M, Orbai A, Alarcon G, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug;64(8):2677-86. doi: 10.1002/art.34473.

18. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2): 288-91.

19. Smirnov AV , Shilov EM, Dobronravov VA, et al. Chronic kidney disease: basic principles of screening, diagnosis, prevention and treatment approaches: national recommendations. http://www.nephro.ru/content/files/standards/ckdru.pdf

20. Gladman DD, Ginzler E, Goldsmith C, et al. The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996 Mar;39(3):363-9. doi: 10.1002/art.1780390303.

21. Nasonova VA. Sistemnaya krasnaya volchanka [Systemic lupus erythematosus]. Moscow: Meditsina; 1972.

22. Barr S, Zonana-Nacach A, Magder L, Petri M. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1999 Dec;42(12):2682-8. doi: 10.1002/1529-0131(199912)42:12<2682::AID-ANR26>3.0.CO;2-6.

23. Dooley M, Aranow C, Ginzler E. Review of ACR renal criteria in systemic lupus erythematosus. Lupus. 2004;13(11):857-60. doi: 10.1191/0961203304lu2023oa.

24. Tareeva IA. Volchanochnyi nefrit [Lupus nephritis]. Moscow: Meditsina; 1976.

25. Ivanova MM. Pathogenetic therapy, rehabilitation and prognosis of patients with systemic lupus erythematosus with predominant kidney damage. Autoref. diss. doct. med. sci. Moscow; 1984. 46 p.

26. Feldman C, Hiraki L, Liu J, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum. 2013 Mar;65(3): 753-63. doi: 10.1002/art.37795.

27. Birmingham D, Bitter J, Ndukwe E, et al. Relationship of Circulating Anti-C3b and Anti-C1q IgG to Lupus Nephritis and Its Flare. Clin J Am Soc Nephrol. 2016 Jan 7; 11(1):47-53. doi: 10.2215/CJN.03990415. Epub 2015 Dec 23.

28. Kwon O, Park J, Lee S, et al. Worse RenalPresentation and Prognosis in Initial-Onset Lupus Nephritis than Early-Onset Lupus Nephritis. Yonsei Med J. 2020 Nov;61(11): 951-7. doi: 10.3349/ymj.2020.61.11.951.

29. Tsokos GC. Systemic lupus erythemato-sus.N Engl J Med. 2011 Dec 1;365(22): 2110-21. doi: 10.1056/NEJMra1100359.

30. International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN); Harley JB, Alarcon-Riquelme ME, Criswell LA, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KI-AA1542 and other loci. Nat Genet. 2008 Feb;40(2):204-10. doi: 10.1038/ng.81. Epub 2008 Jan 20.

31. Hom G, Graham RR, Modrek B, et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med. 2008 Feb 28;358(9):900-9. doi: 10.1056/NEJMoa0707865.

32. Bolin K, Sandling JK, Zickert A, et al. Association of STAT4 polymorphism with severe renal insufficiency in lupus nephritis. PLoS One. 2013 Dec 27;8(12):e84450. doi: 10.1371/journal.pone.0084450.

33. Taylor KE, Chung SA, Graham RR, et al. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genet. 2011 Feb;7(2):e1001311. doi: 10.1371/journal.pgen.1001311.

34. Iwamoto T, Niewold TB. Genetics of human lupus nephritis. Clin Immunol. 2017 Dec;185:32-9. doi: 10.1016/j.clim.2016.09.012